Table 2.

Proof-of-concept of cannabinoids capacity to induce neurogenesis, with the receptor(s) where they are supposed to exert the effects described in the selected works.

Compound	Receptor(s)	Effects	References
ACEA	CB1	Increased proliferation in SVZ. Increased neuronal differentiation.	[86,87,96]
HU-308	CB2	Increased proliferation in SVZ and DG. Increased neuronal differentiation.	[86,87]
WIN-55212-2	CB1 and CB2 TRPV1	Increased proliferation in SVZ and DG. Increased neuronal differentiation. Decreased microglia activation. Decreased microglia activation in DG.	[86,87,98]
THC	CB1	Neuronal differentiation in deep layer. Reduce neurons in upper layer. Altered expression of neurodevelopmental and synaptic function genes. Increased neurogenesis in hippocampus. Increased/decreased cognitive performance †. Worsening/ameliorate locomotion †.	[90,92,94]
CBD	CB1	Increased cell proliferation (low dose). Increased neurogenesis (low dose). Reduce anxiety behaviors. Reduced cell proliferation (high dose). Reduce neurogenesis (high dose).	[93,94]
HU-210	CB1	Induced proliferation of embryonic NSCs and NPCs. Increased hippocampal neurons number. Anxiolytic and antidepressant effects.	[95]
O-1602	GPR55	Increased differentiated neurons number. Increase immature neuron number. Increased proliferation in hNSCs. Increased neuronal differentiation.	[97,99]

Some effects in contrast with previous evidences are marked with †. CB1: Cannabinoid 1; CB2: cannabinoid receptor 2; CBD: cannabidiol; DG: dentate gyrus; GRP55: G protein-coupled receptor 55; NPCs: neuronal progenitor cells; NSCs: neural stem cells; SVZ: subventricular zone; THC: Δ⁹-tetrahydrocannabinol; TRPV1: transient receptor potential cation channel subfamily V member 1.